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Abstract
Background/Aims
Benzimidazoles are efficacious for treating non-resectable alveolar echinococcosis (AE),
but their long-term parasitocidal (curative) effect is disputed. In this study, we prospectively
analyzed the potential parasitocidal effect of benzimidazoles and whether normalization
of FDG-PET/CT scans and anti-Emll/3-10-antibody levels could act as reliable "in vivo"
parameters of AE-inactivation permitting to abrogate chemotherapy with a low risk for AE-
recurrence.
Method
This prospective study included 34 patients with non-resectable AE subdivided into group A
(n = 11), followed-up after diagnosis and begin of chemotherapy at months 6, 12 and 24,
and group B (n = 23) with a medium duration of chemotherapy of 10 (range 2–25) years. All
patients were assessed by FDG-PET/CT examinations and anti-EmII/3-10 serology. Che-
motherapy was abrogated in patients with normalization of FDG-PET/CT and serum anti-
EmII/3-10 levels. These patients were closely followed-up for AE recurrence. Endpoint
(parasitocidal efficacy) was defined by the absence of AE-recurrence >24 months after
stopping treatment.
Results
Normalization of FDG-PET/CT scan and anti-EmII/3-10 levels occurred in 11 of 34 patients
(32%). After abrogation of chemotherapy in these 11 patients, there was no evidence of
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AE-recurrence within a median of 70.5 (range 16–82) months. However, the patients’
immunocompetence appears pivotal for the described long-term parasitocidal effect of
benzimidazoles.
Conclusions
The combination of negative FDG-PET/CT-scans and anti-EmII/3-10 antibody levels seem
to be reliable parameters for assessing in vivo AE-larval inactivity after long-term benzimid-
azole chemotherapy.
Trial Registration
clinicaltrials.gov: NCT00658294
Author Summary
Alveolar echinococcosis is one of the mostly deadly human parasitic diseases if left
untreated. The treatment of choice is surgical resection, followed by two years of benz-
imidazole treatment. Unfortunately, only about 30–40% of patients have a resectable dis-
ease, while the others require medical treatment with benzimidazoles. As this therapy is
only considered to be parasitostatic and as there are not yet reliable tools to assess parasite
viability, the treatment usually is life-long. In this study, we evaluated FDG-PET/CT and
antibody levels against the recombinant Emll/3-10 antigen as markers for parasite viabil-
ity, allowing to select patients in whom chemotherapy could be stopped with low risk of
AE-recurrence. Eleven 11 patients were identified with negative FDG-PET/CT-scans and
anti-EmII/3-10 antibody levels in whom benzimidazole treatment was stopped with no
evidence of AE-recurrence within a median follow-up of 70.5 (range 16–82) months.
Therefore, this study provides evidence that benzimidazole treatment is parasitocidal in a
subset of patients.
Introduction
Alveolar echinococcosis (AE), one of the most Iethal human helminthic infections, is acquired
by ingestion of eggs from Echinococcus multilocularis. AE behaves biologically like a malignant
tumor with a tendency to metastasize into distant organs [1–5]. The treatment of choice is radi-
cal resection, however, only 30–40% of patients have resectable liver lesions [1,4,6,7]. In the
pre-chemotherapy area, the 10-year survival rate of patients with non-resectable AE was less
than 10% [1,8]. With the advent of benzimidazole based chemotherapy, the outcome of non-
resectable AE has dramatically improved. Long-term chemotherapy with benzimidazoles
improves the 10-year survival rate of non-resectable AE to 80% [1,8–10]. However, whether
long-term chemotherapy is parasitocidal (curative) or remains parasitostatic, with the need for
life-long therapy is still unclear [11–15]. The lack of reliable non-invasive methods for assess-
ing parasite viability remains a major problem. Thus, absence of AE-recurrence two to three
years after stopping chemotherapy is retrospectively considered as evidence of a curative effect
[11,12,14].
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Recently, FDG-PET (fluorodeoxy-glucose-positron emission tomography) [16,17] and anti-
body levels against the recombinant EmII/3-10 antigen [18] have been described as two new
promising methods for assessing parasite viability in patients.
Increased FDG-uptake in functional PET-imaging is observed in tumoral, inflammatory
and infectious lesions. Decrease in FDG-uptake is considered as a useful metabolic parameter
for assessing anti-tumoral/anti-infectious pharmacotherapy [19–22]. It was hypothesized that
an increased FDG-uptake of AE lesions reflects parasite viability [16,17]. The reverse assump-
tion that a decrease in FDG-uptake during chemotherapy may be a reliable parameter of para-
site death, however, was not confirmed in a recent study [14].
Serum levels of specific anti-Emll/3-10 antigen appear to be another promising parameter
for parasite viability [18]. In a preliminary study, a putative parasitocidal effect was observed in
two third of patients with non-resectable AE following abrogation of long-term chemotherapy
[12]. A recent follow-up study showed that the anti-Emll/3-10 profile normalized in 8 of 9
patients without AE-recurrence. In contrast, high antibody levels were found in 7 of 9 patients
with AE-recurrence [18].
The aim of the present study was to prospectively evaluate whether long-term chemother-
apy is parasitocidal in patients with AE, and whether FDG-PET/CT in combination with
serum anti-Emll/3-10 levels can be used to select patients in whom chemotherapy can be
stopped with a low risk of AE-recurrence. This is clinically highly relevant because the fre-
quency of AE is rising in Europe and Asia [10,23–25], and the parasite is emerging in parts of
North America [26] and furthermore the costs associated with long-term chemotherapy are
high (up to 16 300 Euro/patient-year) [9].
Methods
Study design
Prospective treatment abrogation study including patients with non-resectable AE and previ-
ous chemotherapy with either albendazole or mebendazole for at least two years. The benz-
imidazole dose was adjusted to reach appropriate serum level 4 hours after the morning dose
(albendazole:>1umol/l, mebendazole:>250 nmol/l) [7].
Inclusion criteria: Non-resectable AE, benzimidazole treatment for at least two years,
absence of FDG uptake (negative FDG-PET/CT scan) and negative anti-EmII/3-10 levels.
Exclusion criteria: Positive FDG-PET/CT scan and/or detectable anti-EmII/3-10 levels,
non-Compliance of the patient, reduced life expectation (age>80 years, concomitant malig-
noma, preterminal disease e.g. renal, hepatic, or pulmonal) and pregnancy.
Patients were selected among a group 34 patients with non resectable AE lesions. Sub-
group A included 11 patients with newly diagnosed AE who had been closely followed by
FDG-PET/CT (at 6, 12 and 24 months) and EmII/3-10 serology during the initial years of
chemotherapy [17]. Subgroup B comprised 23 patients under long term benzimidazole ther-
apy (up to 25 years), who were either inoperable (n = 15) or had either a recurrence after
resection (n = 3) or an R1 resection (n = 5). They were monitored regularly by EmII/3-10
serology (every 6–12 months) and imaging. At variable time intervals after starting albenda-
zole treatment a FDG-PET/CT was obtained.
Patients form both groups that fulfilled the inclusion criteria were included in the study and
stopped treatment. After treatment stop all patients were followed prospectively with Emll/3-
10 serology every 3 months. Imaging studies were performed at start and then every 12 months
or at shorter intervals when AE-recurrence was suspected.
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Ethics statement
The study was performed according to the declaration of Helsinki. The protocol was approved
by the ethical committee of the canton Zurich (Kantonale Ethikkommission des Kanton
Zürich), Switzerland and written informed consent was obtained from all patients (clinical-
trials.gov:NCT00658294).
Study procedures
The FDG-PET/CT protocol has recently been published [21]. Images were analyzed by 2 board
certified nuclear physicians as described previously and a semi-quantitative FDG-uptake grad-
ing scale from 0 to 4 was applied [21].
ELISA using the recombinant Emll/3-10 antigen was performed as previously reported
[18,27]. Antibody levels< 5 AU (arbitrary antibody units) were considered negative.
Echinococcus multilocularis PCR
Echinococcus multilocularis-DNA was detected by PCR in fresh tissue samples obtained at sur-
gery using primers H15 and H17 that amplify a E.multilocularis specific fragment of the mito-
chondrial 12S rRNA gene [28].
Disease classification
The disease stage was classified using the PNM system (S1 Table) [29].
Follow-up
Follow-up (FU) is defined as the time from diagnosis to the last contact, the cut-off date
(December 2012) or the death of the patient.
AE-recurrence was defined if new lesions were detected and/or by progression of lesions on
imaging in association with a positive Emll/3-10 serology and/or a positive PET-CT. A positive
PET-CT alone was not sufficient to diagnose AE-recurrence.
Statistics
Differences between groups were analysed with Chi Square test or Fisher’s exact test using
SPSS software, version 20 (IBM Corporation Armonk, New York, United States). The 95%
Confidence Interval (95% CI) was calculated using RStudio, Version 0.98.1062, 2009–2013
RStudio, Inc.
Results
The baseline demographic of group A patients (n = 11) are summarized in Table 1. Nine
patients had an advanced PNM stage (lllb or IV). Two patients with less advanced AE-Iesions
(stage I to lIIa) were treated by long-term chemotherapy because of serious comorbidity (A1,
A6).
One patient presented with a negative EmII/3-10 serology and PET-negative lesions (A8)
and another one had a negative EmII/3-10 serology at baseline (A5). Nevertheless, both
patients got regular chemotherapy for safety/ study protocol reasons for a minimum of 2 years.
Overall, 5 out of 11 patients of group A qualified for abrogation of chemotherapy and were
included into the study (42%; 95% CI: 16.7–76,6%) (A3, A5, A7, A8, A9).
The pertinent characteristics of group B patients (n = 23) are summarized in Table 2. The
23 patients had been treated for up to 25 years by chemotherapy (median 10, range 2–25
Discontinuation of Long-Term AE Therapy
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years). AE-recurrence following "radical" surgery was observed in 3 patients (B1, B2, B6) and 5
additional patients had undergone R1 surgical resection many years ago (B3, B5, B13, B19, B21
(Table 2). Furthermore, 4 of the 23 patients had AE-recurrence following abrogation of chemo-
therapy in our previous study (B1, B2, B6, B16) [12]. In group B, 7 out of 23 patients qualified
for abrogation of chemotherapy (30%; 95% CI: 13.2–52.9%). Chemotherapy was not stopped
in one of them because of metastatic breast cancer with unclear prognosis (B19).
Patients in group B were significantly younger (median age: 44 yrs. compared to 60 yrs.,
p<0.001), but gender distribution and PNM-classification were similar.
The course and the final assessment of the 11 patients of groups A and B that stopped che-
motherapy, representing the final study population (Fig 1), are summarized in Table 3. The
median follow-up after abrogation of chemotherapy was 70.5 (range 16–82) months. Patients
who qualified for treatment abrogation were significantly older (median age 52 yrs. vs. 44 yrs.;
p<0.001), but gender distribution as well as the number of advanced stages (stage IIIb-IV)
between final study population (Table 3) and group A and B, respectively, (Tables 1 and 2)
were similar.
The clinical course following cessation of chemotherapy was uneventful without any evi-
dence of AE-recurrence in 6 patients. In 5 patients however, the course after cessation of che-
motherapy was complicated by incidental findings (Table 3).
Overall, benzimidazole therapy was probably parasitocidal in at least 32% (11/34; 95% CI
17.4–50.5%) of all patients with non-resectable AE since recurrence was not observed after a
median follow-up of 70.5 (range: 16–82) months following abrogation of chemotherapy (0%,
0/11; 95% CI: 0–28.5%). There was no correlation between the initial size of the FDG-PET/CT
positive lesion and the chemotherapeutic efficacy (shown for patient A9 in whom therapy was
parasitocidal despite an extensive initial lesion (PNM stage P3N1M0; Fig 2)).
Interestingly, anti-Emll/3-10 antibody levels were very high in 5 of 6 subgroup A patients
(126.5 ± 58.6 AU) who did not fulfill the inclusion criteria and in whom no parasitocidal effect
could be noted (A1-2, A4, A6, A10-11). In contrast, the 5 patients in whom a parasitocidal
effect was obvious had substantially lower anti-EmII/3-10 antibody values (30.5 ± 42.9 AU)
(A3, A5, A7-9)(Table 4).
Table 1. Typical findings of 11 newly diagnosed non-resectable AE-patients at baseline and at 2 years of initial chemotherapy. Group A
Nr Sex Age at diagnosis PNM at diagnosis PET grade (0–4) Anti-EmII/3-10 (>5
AU)
Cessation of therapy Comment
at baseline at 2 yrs. at baseline at 2 yrs.
A1 M 39 P3N0M0 2 2 + + no HIV
A2 F 52 P4N0M0 4 2 + + no
A4 F 41 P4N0M0 4 4 + + no
A6 F 72 P1N0M0 3 4 + neg. no Immuno-suppression
A10 M 61 P4N1M0 3 4 + + no
A11 F 55 P4N1M0 3 4 + + no
A3 M 60 P4N0M0 3 0 + neg. yes
A5* F 52 PXN0M0 2 0 neg. neg. yes
A7 F 62 P4NIM0 4 0 + neg. yes
A8 F 60 P4N1M0 0 0 neg. neg. yes
A9 M 64 P3N1M0 4 0 + neg. yes
Median age (range), yrs.: 60 (39–72)
*Recurrence after presumed radical surgery
doi:10.1371/journal.pntd.0003964.t001
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Complicated clinical courses
One patient (A3) underwent a Whipple operation for pancreatic cancer 4 months after abro-
gation of albendazole treatment. At surgery, the hepatic AE-Iesion was resected and no viable
AE-tissue was histologically found. The patient died from metastatic pancreatic cancer 16
months after stopping chemotherapy. No autopsy was performed.
The second patient (A5) underwent a presumed radical hemihepatectomy in 1988 for AE
followed by insufficient mebendazole treatment for only 3 months (Fig 3). In September 2001 a
severe AE-recurrence with a large lesion (7 x 12.5 cm) was detected, which was FDG-PET/CT
positive and showed the typical radiological findings of AE, but anti-Emll/3-10 antibody levels
remained negative. There was a rapid response to chemotherapy (Sept 2001 to Feb 2006).
Albendazole was abrogated in February 2006 despite mild cholestasis that persisted since Dec
2001. In April 2008, endoscopic sphincterotomy with stone extraction was performed. The
procedure was complicated by cholangitis and a perihepatic fluid collection, showing strongly
increased FDG-uptake in FDG-PET/CT. Long-term antibiotic treatment was administered but
no benzimidazole was given. Actually, cholestasis has regressed to almost normal values,
FDG-PET/CT became negative again and anti EmII/3-10 levels remained negative all the time.
Table 2. Typical findings of 23 patients with non-resectable AE treated by chemotherapy for up to 25 years. Group B
Nr Sex Age at
diagnosis
Treatment duration (yrs.) before FDG
PET-CT
PNM PET grade (0–
4)
Anti- EmII/3-10
(>5)
Cessation of
therapy
B1* M 43 22 P3N1M1 0 + no
B2* F 33 24 P3N1M0 3 normal no
B3** F 29 21 P3N1M0 3 + no
B4 F 63 10 P3N1M0 3 normal no
B5** F 51 8 P3N1M0 3 normal no
B6* M 34 22 P4N1M0 0 + no
B7 F 29 14 P3N1M0 3 normal no
B8 F 17 8 P4N0M0 3 + no
B9 F 72 16 P2N1M0 3 normal no
B10 F 59 23 P3N1Mo 3 + no
B11 M 44 4 P3N0M0 3 + no
B12 F 66 4 P3N1M0 3 + no
B19** F 44 25 P3N1M0 0 normal no
B20 M 85 2 P4N1M0 3 normal no
B21** M 48 3 P4N1M0 3 + no
B22 M 44 2 P4N1M0 3 normal no
B23 M 37 3 P4N1M0 3 normal no
B13** M 37 15 P3N0M0 0 normal yes
B14 F 47 4 P3N1M0 0 normal yes
B15 M 52 20 P3N1M0 0 normal yes
B16 F 36 23 P3N0M0 0 normal yes
B17 M 62 6 P1N1M0 0 normal yes
B18 M 45 9 P3N1M1 0 normal yes
Median Age (range), yrs.: 44.0 (17–85)
Median duration of chemotherapy (range), yrs.: 10 (2–25)
* Recurrence after presumed R0 surgery (RR)
** R1 resection
doi:10.1371/journal.pntd.0003964.t002
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A third patient (A7) presented in 2001 with painless jaundice and a large (10 cm) necrotic
AE-Iesion of the right lobe with extension to liver hilum (non-resectable). Response to alben-
dazole treatment was excellent. FDG-PET/CT and EmII/3-10 serology became negative.
Medical treatment was stopped in 2005 despite persistent mild cholestasis. Abrogation of che-
motherapy was followed by marked painless jaundice. ERCP in June 2006 showed a filiform (2
cm) stricture of the common bile duct compatible with "sclerosing-cholangitis" as previously
described [30]. FDG-PET/CT and anti-Emll/3-10 levels remained negative. The biliary
obstruction was successfully treated by endoscopic intervention including stenting. Since AE
recurrence could not be excluded and the patient developed at approximately the same time an
inoperable uterine cancer, which was treated with irradiation and cytostatic therapy, albenda-
zole treatment was resumed and continued until the last follow-up (Oct. 2012), even though a
firm proof of AE recurrence was lacking.
In the next patient (A8), albendazole therapy was carried out from Oct 2002 to Nov 2005
for non-resectable AE (segment V, VI, VII). After treatment abrogation (Nov 05), the clinical
course over the next 3 years was uneventful. In Dec. 2008, a markedly elevated sedimentation
rate (clinically unexplained) was noted which persisted also in July 2009. In Oct. 2009, a new
cystic lesion adjacent to the preexistent AE-Iesion (segment VI) was detected by CT. The anti-
Emll/3-10-antibody levels were negative, and the lesion showed diffusely increased FDG-
uptake in PET/CT. The lesion was resected and a sterile, subacute necro-granulomatous
inflammation of unknown etiology was revealed by histology. Echinococcus multilocularis PCR
Fig 1. Disposition of the study population.
doi:10.1371/journal.pntd.0003964.g001
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results were negative. Therefore, an AE recurrence seemed highly unlikely. Three years, later at
the last follow-up (November 2012), no evidence for AE recurrence was noted.
In patient B14, a non-resectable AE-lesion of the right and caudate liver lobe with partial
occlusion of the portal vein was treated with albendazole between Jul. 2003 and Dec. 2009. The
treatment was well tolerated, and the patient qualified for abrogation of therapy in Dec. 2009.
However, a new cystic lesion was detected by CT in segment VI, adjacent to the previous AE-
lesion. A wait-and-see strategy was adopted with regular follow-up but without resumption of
chemotherapy. Follow-up was uneventful, and a CT scan showed a calcified scar, but no evi-
dence of AE-recurrence in Nov. 2012.
Discussion
Our prospective long-term study provides strong evidence that chemotherapy was parasitoci-
dal in at least 11 out of 34 patients (32%) with non-resectable AE. These results contradict the
current opinion of an exclusively parasitostatic effect with the need for lifelong medical ther-
apy [2–4,7,9,14]. Moreover, patient follow-ups by FDG-PET/CT and Emll/3-10 serology rep-
resent a strategy to assess parasite viability and to decide whether treatment can be safely
discontinued.
Our data seem to be in discordance with a clinical study including 23 patients with non-
resectable AE in Ulm (Germany) [14]. Based on negative FDG-PET-scans, benzimidazole ther-
apy of variable duration was stopped in 15 patients, but evidence of AE-recurrence was noted
in 53% within the following 18 months. These data suggested a poor correlation between
FDG-PET-scan results and larval viability [14].
Table 3. Follow-up (FU) after abrogation of chemotherapy in non-resectable AE.
Nr Sex Age at
diagnosis
(yrs.)
Treatment duration
(mo) before treatment
abrogation
Follow-up after
stopping therapy
(mo)
EmII/3-
10 (>5)
Final assessment
A9 M 64 34 71 normal No AE recurrence
A7 F 62 36 70 normal No AE-recurrence: Short stricture of hepatic duct due
sclerosing cholangitis. Successful endoscopic treatment.
A8 F 60 36 70 normal New PET pos. lesion close to AE-scar at 48 months.
Surgery: necro-granulomatous lesion. AE unlikely. No
chemo-therapy. Follow-up two years later: scar
A3 M 60 37 16 normal Died due to pancreatic cancer. No AE activity in resection
specimen
B14 F 47 41 60 normal 37 mo. After stopping chemotherapy new cystic, PET
negative lesion close to AE-scar. AE recurrence unlikely.
PET neg scar after two additional year of follow-up
A5 F 52 50 68 normal No AE recurrence
Choledocholithiasis
B17 M 62 78 82 normal No AE recurrence
B18 M 45 108 75 normal No AE recurrence
B13 M 37 180 56 normal No AE recurrence
B15 M 52 240 78 normal No AE recurrence
B16 F 36 276 76 normal No AE recurrence
Median age (range), yrs.: 52 (36–64)
Median duration of treatment (range), mo.: 50 (34–276)
Follow-up after stopping treatment (range), mo.: 70 (16–82)
doi:10.1371/journal.pntd.0003964.t003
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In contrast to our study (33% negative FDG-PET/CT), the rate of FDG-PET negative lesions
after long-term chemotherapy was surprisingly high (65%) in the Ulm study.
In previous studies, the interval between abrogation of chemotherapy and AE recurrence
averaged 33.6 (range 12–156) months [12,18] and less than 18 months [14]. No AE-recurrence
was noted on an average 29.2 (range 6.8–66) and 23 (range 8–37) months, respectively, after
cessation of chemotherapy in two recent series from the same group (n = 5 and n = 7) [31,32].
Fig 2. (A9): Baseline and follow-up FDG-PET/CT scans without i.v. contrast. a) Large and small AE-
lesions (arrow) at the time of diagnosis (2003) with very strongly increased FDG uptake. b) The lesions
became FDG-negative within two years of albendazole treatment. c) Progressive calcifications of AE lesions
over the next 6 years after abrogation of chemotherapy (2011). No signs of FDG uptake are present.
doi:10.1371/journal.pntd.0003964.g002
Table 4. Long-term follow-up of anti-EmII/3-10 levels in patients of group A.
Baseline 6 months 12 months 24 months 36 months 48 months 60 months 72 months 84 months 96 months
A1 132 92 57 12 7 0 5 11 7
A2 172 151 133 84 98 109 150
A3 41 19 0 0 0 0 0
A4 145 128 119 128 183 253 262 212 103
A5 0 0 0 0 0 0 0 0 0 0
A6 11 0 0 0 0 0 0
A7 110 75 72 0 0 0 0 0 0 0
A8 0 0 0 0 0 0 0 0 0 0
A9 32 0 0 0 0 0 0 0 0
A10 133 103 112 53 50 10 39 24
A11 166 144 127 124 160 276 265 238
doi:10.1371/journal.pntd.0003964.t004
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In the present series, the patients were followed for a median of 70 (range 16–82) months
after abrogation of chemotherapy. Accordingly, the risk of missing AE-recurrence after stop-
ping chemotherapy in our series appears small, although AE-recurrence has been reported in
single cases after 106 [33] and 156 months [8] respectively.
The problem of diagnosing AE-recurrence following abrogation of chemotherapy is illus-
trated by the numerous incidental findings in our series (A3, A5, A7, A8, B14). In particular,
cholestasis after chemotherapy abrogation was probably not caused by AE-recurrence (A5,
A7), since follow-up data were compatible with a sclerosing-cholangitis like syndrome, a
largely unknown syndrome [30] in one and oligosymptomatic (incidental) choledocholithiasis
in the second patient.
Two patients of our series developed new liver lesions (A8, B14). Causes are unexplained,
but AE-recurrence seemed very unlikely particularly because levels of specific antibodies
(including anti-Emll/3-10 antibodies) remained unchanged and no lesion progression was
observed during a three year follow-up period without chemotherapy.
Fig 3. (A5): Long-term follow-up of a large AE recurrence (Sept 2001), 3 years following presumed radical surgery). Albendazole was administered
from Sept. 2001 until February 2006. Oligosymptomatic choledocholithiasis was treated by ERCP with papillotomy and stone extraction in April 2008. The
procedure was complicated by cholangitis, which was treated by long-term antibiotic therapy. No AE-recurrence was noted during 70 months of follow-up
after stopping albendazole treatment.
doi:10.1371/journal.pntd.0003964.g003
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According to the current literature, the predictive value of post-chemotherapy immunsur-
veillance is limited [2,4,9,34,35]. In contrast, our data indicate that anti-EmII/3-10 levels are
valuable for assessing parasite viability ([18], present series). In our experience, the anti-Emll/
3-10 levels are more sensitive markers for larval viability than the serological results obtained
by the Em2-plus test containing two antigens (Em2 and EmII/3-10) [36] used by Reuter et al.
[14].
Surprisingly, we found that baseline anti-Emll/3-10 levels appear to have a predictive value
with regard to a parasitocidal efficacy of albendazole treatment. These levels were very high
(>120 AU units) in 5 of 6 patients of group A in whom no parasitocidal effect was observed, in
contrast to the 5 patients with low levels (< 120 AU) in whom there was a probable parasitoci-
dal effect (Fig 3). The predictive value of baseline anti-EmII/3-10 serology for parasitocidal vs.
parasitostatic efficacy deserves further studies in larger series of AE patients.
It is largely unknown which factor(s) are important for the parasitocidal effect of benzimid-
azole treatment. It has been suggested that a parasitocidal effect may be related to the duration
of therapy [11,15]. This assumption was not confirmed in recent studies [14] and the present
series. In particular, no parasitocidal efficacy was noted in the majority of 23 patients (group B)
despite chemotherapy for up to 25 years (Table 2).
The parasite host-immune-interaction probably plays an important role for the outcome of
AE-infection [37]. First, AE-lesions may be inactivated spontaneously i.e. “died-out” AE
[2,4,37,38]. Second, the impact of immune deficiency as (co)-factor for lacking parasitocidal
efficacy is supported by 2 patients in group A, i.e. HIV-infection (A1) or continuous immuno-
suppressive therapy (rheumatoid arthritis; A6). According to a recent French series, a family
clustering of AE was noted in 20 of 153 patients (13%) [39]. Such an association was not
observed in our series. Third, AE progression in AIDS [40] or in immune-compromised
patients following liver transplantation [41] as well as in animal experiments with cyclospor-
ine-induced immunodeficiency [42] emphasize the impact of an intact immune system on the
evolution of AE disease.
In conclusion, according to our knowledge, this is the largest prospective study document-
ing a parasitocidal efficacy of long-term benzimidazole chemotherapy in 11 patients with AE.
Negative anti-EmII/3-10 levels combined with normalized FDG-PET scan were reliable
parameters to predict a recurrence-free survival after stopping benzimidazole treatment. Until
our data are confirmed long-term benzimidazole treatment is still the standard of care for
patients with unresectable AE, after R1 resection or after liver transplantation [2]. To stop
long-term benzimidazole treatment should only be considered in experienced center using the
same approach as outlined in this manuscript. Especially positive PET-CT findings should be
carefully evaluated and the diagnosis of recurrence should not be based on an isolated positive
PET/CT finding alone. In addition it is mandatory that patients are closely followed and there-
fore stopping long-term benzimidazole treatment should only be considered in patients who
will be compliant with follow-up examinations. In our previous study we could show that espe-
cially monitoring with the EmII/3-10 serology is very useful to predict recurrence [18]. Finally
as patients safety is crucial, restarting benzimidazole treatment should also be considered in
patients requiring any kind of immunosuppressive treatment such as chemotherapy.
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